This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Omnicell's OmniLinkRx Honored With KLAS Award For Medication Order Management Systems

 

MOUNTAIN VIEW, Calif., Jan. 5, 2012 /PRNewswire/ --  Omnicell , Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced that KLAS, a prestigious third-party healthcare evaluation firm, awarded Omnicell's OmniLinkRx® with the Category Leader distinction for Medication Order Management Systems in the 2011 Best in KLAS Awards: Software & Services report. This is the third consecutive year that OmniLinkRx has received this award.

OmniLinkRx automates communication of medication orders between nursing and the pharmacy, improving efficiency and productivity for both departments. OmniLinkRx can also be used as a complement to Computerized Physician Order Entry (CPOE) installations. By integrating easily and coexisting with the rest of the pharmacy information system, OmniLinkRx helps eliminate interruptions caused by lost, misplaced or illegible paperwork that can often delay patient therapy. OmniLinkRx allows for faster order time, reduced time spent processing and verifying medication orders, elimination of paper management, and improved pharmacy support to nursing units.

OmniLinkRx was rated highest in overall satisfaction for medication order management systems and in the KLAS "buy again" category, 94 percent of hospital executives polled said they would buy OmniLinkRx again.

"Since 1998, KLAS has been committed to helping healthcare providers make decisions based on candid peer feedback," says Adam Gale, KLAS president. "Best in KLAS rankings mark those vendors who best keep their promises in their market segments for offering a combination of superior products, strong service, and high customer value. We hope these ratings continue to help providers find transparency from their vendors in making purchasing decisions."

Omnicell also received a KLAS ranking for the OmniRx® automated dispensing system for six consecutive years. From 2006 to 2009, OmniRx was awarded as the Product Leader in automated dispensing systems. In 2010 and 2011, OmniRx was awarded the "Best in KLAS" distinction for Automated Medication Dispensing Cabinets (over 200 beds) as well as Category Leader for hospitals under 200 beds. In 2010 and 2011, Omnicell was also awarded Category Leader for Pharmacy Automation Medication Carousels for its WorkflowRx™ and carousel. In 2011, Omnicell received yet another KLAS Category Leader award for its Anesthesia Workstation, the first time this market segment was eligible for KLAS distinction.

"We are pleased that our customers continue to validate our technology and service as illustrated by the consistent KLAS rankings in so many market segments," said Marga Ortigas-Wedekind, Omnicell vice president, global marketing and product development. "We are honored to receive the third consecutive KLAS award for OmniLinkRx and to be recognized by our customers and KLAS as the industry leader in medication order management systems."

About Omnicell

Omnicell, Inc. (NASDAQ: OMCL) is a leading provider of automated and business information solutions enabling hospitals and healthcare systems to streamline the medication administration process and manage costly medical supplies for increased operational efficiency and enhanced patient safety. Through seamless integration with a hospital's existing IT infrastructure, Omnicell solutions empower healthcare facilities to achieve comprehensive automation of medication and supply management from the arrival at the loading dock to the patient's bedside. Omnicell also provides healthcare facilities with business analytics software designed to improve medication diversion detection and regulatory compliance.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs